A Phase 3 interventional study of Soticlestat and Placebo in Dravet Syndrome (DS), sponsored by Takeda. Completed at 66 sites in 18 countries. Open to participants aged 2 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS.
Participants will receive their standard antiseizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo looks just like soticlestat but will not have any medicine in it.
Participants may continue treatment in an extension study, based on the extension study's entry criteria. Those that want to stop treatment will have a gradual dose reduction during 1 week and then be followed up for 2 weeks.
The drug being tested in this study is called soticlestat (TAK-935). Soticlestat as an adjunctive therapy will be assessed for efficacy, safety, and tolerability in pediatric and adult participants with DS.
The study will enroll approximately 142 pediatric and young adult patients. Participants will be randomized at a 1:1 ratio to receive standard of care (SOC) plus one of the following adjunctive therapies:
The total daily dose of study drug will be calculated based on body weight in the 4 weeks Titration Period. Following the Titration Period, participants will continue to receive the same dose in the 12-weeks Maintenance Period.
This multi-center trial will be conducted worldwide. The overall time to participate in the study will be from 22-25 weeks. At the end of the Full Treatment Period, participants have the option to either complete the study and taper off the investigational product or to enter the OLE if they meet eligibility requirements. If participants discontinue, they will be followed-up on phone call approximately 14 days after the last dose of study drug for safety.
87 studies on the registry are indexed under Epilepsies, Myoclonic; 23 are open to participants now.
This study's enrollment of 144 is above the median of 25 across 54 interventional studies indexed under Epilepsies, Myoclonic.
Browse Epilepsies, Myoclonic studies →Takeda is the lead sponsor of 1,002 studies on the registry; 92 are open to participants now.
Of its 173 completed or terminated interventional studies of FDA-regulated products, 149 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1. Unstable, clinically significant neurologic (other than the disease being studied), psychiatric, cardiovascular, ophthalmologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, endocrine disease, malignancy including progressive tumors, or other abnormality that may impact the ability to participate in the study or that may potentially confound the study results. It is the responsibility of the investigator to assess the clinical significance; however, consultation with the medical monitor may be warranted.
Soticlestat placebo-matching mini-tablets or tablets, orally or via gastrostomy tube (G-tube) or low-profile gastric tube (MIC-KEY) button or jejunostomy tube (J-tube), twice daily (BID), up to 4 weeks during titration. Participants continued to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks during maintenance. The total duration of the treatment was up to 16 weeks (Full Treatment Period). Soticlestat matching tapering was done to maintain the blind if participants decided to discontinue the treatment.
Drug: Placebo
Participants weighing \<45 kg: Soticlestat, mini-tablets, at the dose of 40 mg to 200 mg, orally or via G-tube or MIC-KEY button or J-tube, BID based on the body weight up to 4 weeks during titration. Participants continued to receive the dose that they were on at the end of the titration, for 12 weeks during maintenance. The total duration of the treatment was up to 16 weeks (Full Treatment Period) with dose tapered down if participants decided to discontinue the treatment. Participants weighing ≥45 kg: Soticlestat mini-tablets or tablets with a starting dose of 100 mg BID followed by 200 mg BID and, then 300 mg BID, up to 4 weeks during titration. Participants continued to receive 300 mg BID for 12 weeks during maintenance. The total duration of the treatment was up to 16 weeks (Full Treatment Period) with dose tapered down if participants decided to discontinue the treatment.
Drug: Soticlestat
Soticlestat mini-tablets or tablets.
Also known as: TAK-935
Soticlestat placebo-matching mini-tablets or tablets.
Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period
Convulsive seizure frequency per 28 days was defined as the total number of convulsive seizures reported during the period divided by the number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during the Full Treatment Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
Time frame: Baseline; Full Treatment Period: Weeks 1 to 16
Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Maintenance Period
Convulsive seizure frequency per 28 days was defined as the total number of convulsive seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during Maintenance Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
Time frame: Baseline; Maintenance Period: Weeks 5 to 16
Percentage of Responders During Maintenance Period
Responders were defined as those with ≥50% reduction from Baseline in convulsive seizures during the Maintenance Period. Percentages were rounded off to the nearest single decimal place.
Time frame: Maintenance Period: Weeks 5 to 16
Percentage of Responders During the Full Treatment Period
Responders were defined as those with ≥50% reduction from Baseline in convulsive seizures during the Full Treatment Period. Percentages were rounded off to the nearest single decimal place.
Time frame: Full Treatment Period: Weeks 1 to 16
Percentage of Participants With ≤0%, >0% to ≤25%, >25% to ≤50%, >50% to ≤75%, and >75% to ≤100% Reduction in Convulsive Seizures During the Full Treatment Period
Percent reduction from Baseline (%) was defined as \[(Full Treatment Period Convulsive Seizure Frequency - Baseline Convulsive Seizure Frequency) divided by Baseline Convulsive Seizure Frequency\] multiplied by 100. Data was reported as reduction of ≤0%, \>0% to ≤25%, \>25% to ≤50%, \>50% to ≤75%, \>75% to ≤100% or more in seizures from Baseline. Percentages were rounded off to the nearest single decimal place.
Time frame: Full Treatment Period: Weeks 1 to 16
Percentage of Participants With Caregiver Global Impression of Improvement (Care GI-I) Scale Responses as Per the Parent/Caregiver Reported Impression at Week 16
The Care GI-I is a 7-point Likert scale that the caregiver used to rate improvement in overall seizure control, behavior, safety and tolerability after the initiation of study drug relative to Baseline (before treatment with the study drug). The participant was rated as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). The parent/caregiver completed the Care GI-I via interview. Lower scores indicate improvement. Percentages were rounded off to the nearest single decimal place.
Time frame: Week 16
Percentage of Participants With Clinical Global Impression of Improvement (CGI-I) Scale Responses as Per the Investigator Reported Impression at Week 16
The CGI-I (Clinician) is a 7-point Likert scale that the investigator used to rate a participant's change (improvement) in overall seizure control, behavior, safety and tolerability, after the initiation of study drug relative to Baseline (before treatment with the study drug). The participant was rated as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). The investigator or designee completed the CGI-I. Lower scores indicate improvement. Percentages were rounded off to the nearest single decimal place.
Time frame: Week 16
Percentage of Participants With CGI-I Nonseizure Symptoms Instrument Responses for Each Domain as Per the Investigator Reported Impression at Week 16
The CGI-I non-seizure symptoms instrument is a series of single-item assessments that the investigator used to rate improvement in the symptoms and impacts in select non-seizure domains (alertness, communication, and disruptive behaviors) since initiating the study drug. The participant was rated by the investigator for each domain as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Lower scores indicated improvement. Data for percentage of participants categorized based on the responses for each domain are presented. Percentages were rounded off to the nearest single decimal place.
Time frame: Week 16
Change From Baseline in Quality of Life Inventory-Disability (QI-Disability) Total Score at Week 16
The QI-Disability tool is a parent/caregiver-reported questionnaire that evaluated the quality of life in children with intellectual disabilities. It contains 32 items covering 6 domains of quality of life: physical health, positive emotions, negative emotions, social interaction, leisure and the outdoors, and independence. Each QI-Disability item is rated on a Likert scale of: Never, Rarely, Sometimes, Often, and Very Often. Items were linearly transformed to a scale of 0 to 100, with higher scores representing better quality of life. Domain scores are calculated by averaging item scores. The domain scores are summed and divided by 6 to yield a total score. The total score ranges from 0 to 100, with higher scores indicating a better quality of life. A negative change from Baseline implies deteriorating quality of life. Mixed-effects model for repeated measures (MMRM) was used for analysis.
Time frame: Baseline, Week 16
Percentage of Participants With CGI-I Seizure Intensity and Duration Instrument Responses as Per the Parent/Caregiver Reported Impression at Week 16
The CGI-I seizure intensity and duration instrument was used by the parent/caregiver to rate changes in intensity and/or duration of the most impactful seizures from the first assessment. The participant's symptoms were rated on 7-point scale as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Lower scores indicate improvement. Percentages were rounded off to the nearest single decimal place.
Time frame: Week 16
Percent Change From Baseline in Frequency of All Seizures Per 28 Days During the Maintenance Period
Seizure frequency per 28 days was defined as the total number of seizures reported during the period divided by the number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during the Maintenance Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
Time frame: Baseline; Maintenance Period: Weeks 5 to 16
Percent Change From Baseline in Frequency of All Seizures Per 28 Days During the Full Treatment Period
Seizure frequency per 28 days was defined as the total number of seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during the Full Treatment Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
Time frame: Baseline; Full Treatment Period: Weeks 1 to 16
Change From Baseline in Percentage of Convulsive Seizure-free Days During the Full Treatment Period
Convulsive seizure-free days was defined as number of days a participant remained convulsive seizure-free after initiation of the treatment. The change from baseline in percentage of convulsive seizure-free days, was defined as the percentage of seizure-free days during the Full Treatment Period minus the percentage of seizure-free days during the Baseline. A linear model with treatment group and age stratum as factors and baseline percentage as a covariate was used for analysis.
Time frame: Baseline up to Week 16
Longest Convulsive Seizure-free Interval During the Full Treatment Period
Longest convulsive seizure-free interval was defined as the longest time period that the participant remained convulsive seizure free after initiation of the treatment. A linear model with treatment group and age stratum as factors was used for analysis.
Time frame: Full Treatment Period: Weeks 1 to 16
Number of Days When Rescue Antiseizure Medication (ASM) is Used During the Full Treatment Period
Use of rescue ASM was recorded in the case report form (CRF) along with start and end date of medication. Based on the start and end dates for all rescue ASMs taken by a participant, the number of days during the Full Treatment Period when rescue ASM was used was derived.
Time frame: Full Treatment Period: Weeks 1 to 16
A total of 144 participants participated in the study at multiple investigative sites globally from 28 October 2021 to 11 April 2024.
| Milestone | Placebo | Soticlestat |
|---|---|---|
| Started | 71 | 73 |
| Completed | 63 | 60 |
| Not completed | 8 | 13 |
| Withdrew: Adverse event | 4 | 11 |
| Withdrew: Withdrawal by parent/guardian | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Reason not specified | 1 | 0 |
Convulsive seizure frequency per 28 days was defined as the total number of convulsive seizures reported during the period divided by the number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during the Full Treatment Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
| percent change | Placebo | Soticlestat |
|---|---|---|
| Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period | -8.64 (-30.13 to 14.83) | -22.16 (-53.64 to 22.73) |
Convulsive seizure frequency per 28 days was defined as the total number of convulsive seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during Maintenance Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
| percent change | Placebo | Soticlestat |
|---|---|---|
| Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Maintenance Period | -11.99 (-31.93 to 9.75) | -23.29 (-56.92 to 14.15) |
Responders were defined as those with ≥50% reduction from Baseline in convulsive seizures during the Maintenance Period. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| Percentage of Responders During Maintenance Period | 11.8 | 30.4 |
Responders were defined as those with ≥50% reduction from Baseline in convulsive seizures during the Full Treatment Period. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| Percentage of Responders During the Full Treatment Period | 9.9 | 27.4 |
Percent reduction from Baseline (%) was defined as \[(Full Treatment Period Convulsive Seizure Frequency - Baseline Convulsive Seizure Frequency) divided by Baseline Convulsive Seizure Frequency\] multiplied by 100. Data was reported as reduction of ≤0%, \>0% to ≤25%, \>25% to ≤50%, \>50% to ≤75%, \>75% to ≤100% or more in seizures from Baseline. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| ≤0% Reduction | 39.4 | 31.5 |
| >0% to ≤25% Reduction | 32.4 | 20.5 |
| >25% to ≤50% Reduction | 18.3 | 20.5 |
| >50% to ≤75% Reduction | 8.5 | 13.7 |
| >75% to ≤100% Reduction | 1.4 | 13.7 |
The Care GI-I is a 7-point Likert scale that the caregiver used to rate improvement in overall seizure control, behavior, safety and tolerability after the initiation of study drug relative to Baseline (before treatment with the study drug). The participant was rated as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). The parent/caregiver completed the Care GI-I via interview. Lower scores indicate improvement. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| Score 1: Very Much Improved | 1.5 | 4.5 |
| Score 2: Much Improved | 11.8 | 27.3 |
| Score 3: Minimally Improved | 22.1 | 28.8 |
| Score 4: No Change | 47.1 | 27.3 |
| Score 5: Minimally Worse | 10.3 | 7.6 |
| Score 6: Much Worse | 5.9 | 3.0 |
| Score 7: Very Much Worse | 1.5 | 1.5 |
The CGI-I (Clinician) is a 7-point Likert scale that the investigator used to rate a participant's change (improvement) in overall seizure control, behavior, safety and tolerability, after the initiation of study drug relative to Baseline (before treatment with the study drug). The participant was rated as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). The investigator or designee completed the CGI-I. Lower scores indicate improvement. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| Score 1: Very Much Improved | 2.8 | 7.0 |
| Score 2: Much Improved | 8.5 | 25.4 |
| Score 3: Minimally Improved | 15.5 | 19.7 |
| Score 4: No Change | 59.2 | 38.0 |
| Score 5: Minimally Worse | 5.6 | 8.5 |
| Score 6: Much Worse | 8.5 | 1.4 |
| Score 7: Very Much Worse | 0.0 | 0.0 |
The CGI-I non-seizure symptoms instrument is a series of single-item assessments that the investigator used to rate improvement in the symptoms and impacts in select non-seizure domains (alertness, communication, and disruptive behaviors) since initiating the study drug. The participant was rated by the investigator for each domain as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Lower scores indicated improvement. Data for percentage of participants categorized based on the responses for each domain are presented. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| Alertness: Score 1: Very Much Improved | 2.8 | 7.0 |
| Alertness: Score 2: Much Improved | 8.5 | 4.2 |
| Alertness: Score 3: Minimally Improved | 14.1 | 14.1 |
| Alertness: Score 4: No Change | 67.6 | 70.4 |
| Alertness: Score 5: Minimally Worse | 5.6 | 4.2 |
| Alertness: Score 6: Much Worse | 1.4 | 0.0 |
| Alertness: Score 7: Very Much Worse | 0.0 | 0.0 |
| Communication: Score 1: Very much Improved | 1.4 | 4.2 |
| Communication: Score 2: Much Improved | 11.3 | 5.6 |
| Communication: Score 3: Minimally Improved | 18.3 | 22.5 |
| Communication: Score 4: No Change | 62.0 | 62.0 |
| Communication: Score 5: Minimally Worse | 4.2 | 4.2 |
| Communication: Score 6: Much Worse | 2.8 | 1.4 |
| Communication: Score 7: Very Much Worse | 0.0 | 0.0 |
| Disruptive Behaviors: Score 1: Very Much Improved | 1.4 | 1.4 |
| Disruptive Behaviors: Score 2: Much Improved | 4.2 | 5.6 |
| Disruptive Behaviors: Score 3: Minimally Improved | 14.1 | 16.9 |
| Disruptive Behaviors: Score 4: No Change | 69.0 | 64.8 |
| Disruptive Behaviors: Score 5: Minimally Worse | 11.3 | 8.5 |
| Disruptive Behaviors: Score 6: Much Worse | 0.0 | 1.4 |
| Disruptive Behaviors: Score 7: Very Much Worse | 0.0 | 1.4 |
The QI-Disability tool is a parent/caregiver-reported questionnaire that evaluated the quality of life in children with intellectual disabilities. It contains 32 items covering 6 domains of quality of life: physical health, positive emotions, negative emotions, social interaction, leisure and the outdoors, and independence. Each QI-Disability item is rated on a Likert scale of: Never, Rarely, Sometimes, Often, and Very Often. Items were linearly transformed to a scale of 0 to 100, with higher scores representing better quality of life. Domain scores are calculated by averaging item scores. The domain scores are summed and divided by 6 to yield a total score. The total score ranges from 0 to 100, with higher scores indicating a better quality of life. A negative change from Baseline implies deteriorating quality of life. Mixed-effects model for repeated measures (MMRM) was used for analysis.
| score on a scale | Placebo | Soticlestat |
|---|---|---|
| Change From Baseline in Quality of Life Inventory-Disability (QI-Disability) Total Score at Week 16 | 2.81 ± 10.119 | -1.23 ± 15.438 |
The CGI-I seizure intensity and duration instrument was used by the parent/caregiver to rate changes in intensity and/or duration of the most impactful seizures from the first assessment. The participant's symptoms were rated on 7-point scale as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Lower scores indicate improvement. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Placebo | Soticlestat |
|---|---|---|
| Score 1: Very Much Improved | 4.3 | 10.8 |
| Score 2: Much Improved | 4.3 | 24.6 |
| Score 3: Minimally Improved | 15.9 | 23.1 |
| Score 4: No Change | 59.4 | 33.8 |
| Score 5: Minimally Worse | 5.8 | 1.5 |
| Score 6: Much Worse | 8.7 | 6.2 |
| Score 7: Very Much Worse | 1.4 | 0.0 |
Seizure frequency per 28 days was defined as the total number of seizures reported during the period divided by the number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during the Maintenance Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
| percent change | Placebo | Soticlestat |
|---|---|---|
| Percent Change From Baseline in Frequency of All Seizures Per 28 Days During the Maintenance Period | -11.89 (-33.78 to 10.50) | -17.24 (-56.83 to 23.70) |
Seizure frequency per 28 days was defined as the total number of seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline was defined as (frequency of seizures per 28 days during the Full Treatment Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.
| percent change | Placebo | Soticlestat |
|---|---|---|
| Percent Change From Baseline in Frequency of All Seizures Per 28 Days During the Full Treatment Period | -7.46 (-32.37 to 14.83) | -9.27 (-54.11 to 30.00) |
Convulsive seizure-free days was defined as number of days a participant remained convulsive seizure-free after initiation of the treatment. The change from baseline in percentage of convulsive seizure-free days, was defined as the percentage of seizure-free days during the Full Treatment Period minus the percentage of seizure-free days during the Baseline. A linear model with treatment group and age stratum as factors and baseline percentage as a covariate was used for analysis.
| percentage of days | Placebo | Soticlestat |
|---|---|---|
| Change From Baseline in Percentage of Convulsive Seizure-free Days During the Full Treatment Period | 2.74 ± 1.784 | 3.54 ± 1.719 |
Longest convulsive seizure-free interval was defined as the longest time period that the participant remained convulsive seizure free after initiation of the treatment. A linear model with treatment group and age stratum as factors was used for analysis.
| days | Placebo | Soticlestat |
|---|---|---|
| Longest Convulsive Seizure-free Interval During the Full Treatment Period | 16.7 ± 2.15 | 22.3 ± 2.08 |
Use of rescue ASM was recorded in the case report form (CRF) along with start and end date of medication. Based on the start and end dates for all rescue ASMs taken by a participant, the number of days during the Full Treatment Period when rescue ASM was used was derived.
| days | Placebo | Soticlestat |
|---|---|---|
| Number of Days When Rescue Antiseizure Medication (ASM) is Used During the Full Treatment Period | 4.0 ± 0.81 | 2.9 ± 0.78 |
Collected over From the first dose up to Week 19. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/71 (0%) | 10/71 (14.1%) | 37/71 (52.1%) |
| Soticlestat | 1/73 (1.4%) | 7/73 (9.6%) | 40/73 (54.8%) |
| Event | Placebo | Soticlestat |
|---|---|---|
| Status epilepticusNervous system disorders | 4/71 | 2/73 |
| Seizure clusterNervous system disorders | 1/71 | 2/73 |
| Adenovirus infectionInfections and infestations | 1/71 | 0/73 |
| COVID-19 pneumoniaInfections and infestations | 1/71 | 0/73 |
| Infectious mononucleosisInfections and infestations | 1/71 | 0/73 |
| PneumoniaInfections and infestations | 1/71 | 0/73 |
| Respiratory tract infectionInfections and infestations | 1/71 | 1/73 |
| SeizureNervous system disorders | 1/71 | 0/73 |
| BronchitisInfections and infestations | 0/71 | 1/73 |
| Pneumonia mycoplasmalInfections and infestations | 0/71 | 1/73 |
| Event | Placebo | Soticlestat |
|---|---|---|
| Change in seizure presentationNervous system disorders | 9/71 | 10/73 |
| SomnolenceNervous system disorders | 8/71 | 10/73 |
| NasopharyngitisInfections and infestations | 9/71 | 9/73 |
| PyrexiaGeneral disorders | 9/71 | 8/73 |
| Upper respiratory tract infectionInfections and infestations | 8/71 | 6/73 |
| ConstipationGastrointestinal disorders | 0/71 | 6/73 |
| InsomniaPsychiatric disorders | 1/71 | 6/73 |
| Decreased appetiteMetabolism and nutrition disorders | 4/71 | 5/73 |
| FatigueGeneral disorders | 4/71 | 2/73 |
Safety Analysis Set included all participants who had taken at least one dose of study drug.
| Age, Continuous(years) | Placebo | Soticlestat | Total |
|---|---|---|---|
| Mean | 10.5 ± 5.06 | 10.1 ± 5.04 | 10.3 ± 5.04 |
| Sex: Female, Male(Participants) | Placebo | Soticlestat | Total |
|---|---|---|---|
| Female | 35 | 37 | 72 |
| Male | 36 | 36 | 72 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Soticlestat | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 11 |
| Not Hispanic or Latino | 62 | 68 | 130 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | Soticlestat | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 24 | 27 | 51 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 3 |
| White | 43 | 39 | 82 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 4 | 2 | 6 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Sap, Icf, Csr
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Takeda